(PharmaNewsWire.Com, October 07, 2020 ) Market growth is largely driven by factors such as technological advancements, the rising prevalence of breast cancer, the increasing number of screening programsas well as rising number of conferences and symposiums focusing on spreading awareness about the benefits of early screening and diagnosis. The emerging markets, growing government and private investments to meet the increasing demand for breast cancer screening, and the improving reimbursement scenario are expected to present a wide range of growth opportunities for market players. The breast imaging market is projected to grow from an estimated USD 3.7 billion in 2020 to USD 5.4 billion by 2025, at a CAGR of 8.1% during the forecast period.
Based on technology, the breast imaging market is segmented into ionizing breast imaging and non-ionizing breast imaging technologies. The non-ionizing breast imaging segment is expected to grow at the highest CAGR during the forecast period. Growth inthis segment can be attributed to the advantages offered by non-ionizing breast imaging technologies over ionizing breast imaging technologies, such as greater generation of anatomical details for diagnosis, high sensitivity to small breast lesions in women with dense breast tissues, and fewerfalse positives.
The market for ionizing breast imaging technologies, by type, comprises mammography (analog mammography, full-field digital mammography, and 3D breast tomosynthesis), positron emission tomography-computed tomography (PET-CT), molecular breast imaging/breast-specific gamma imaging (MBI/BSGI), positron emission mammography (PEM), and cone-beam computed tomography (CBCT). Mammography accounted for the largest share of the ionizing breast imaging technologies market in 2019. Its large share can beattributed to technological advancements in this segment and increasing awareness.
Non-ionizing breast imaging technologies comprise breast ultrasound, breast MRI, automated whole-breast ultrasound (AWBU), breast thermography, electric impedance tomography, and optical imaging. The breast ultrasound segment accounted for the largest share of the non-ionizing breast imaging technologies market in 2019 whereas the AWBU segment is estimated to witness the second-highest growth rate during the forecast period. The large share of the breast ultrasound segment can beattributed to the lower risk of exposure to radiation and the benefits offered by breast ultrasound such as the ability to detect lesions and the nature of lesions in women with dense breast tissues, the ability to differentiate between a cyst and a solid mass, and the detection of blood flow through vessels.
Geographical Region
The Asia Pacific is one of the major revenue-generating regions in the breast imaging market. The rising prevalence of breast cancer, increasing healthcare expenditure, increasing number of awareness programs for the early detection of breast cancer, and the high government spending on breast cancer research studies in several APAC countries are the major factors driving the growth of the breast imaging market in Asia Pacific. As per GLOBOCAN 2018, a total of 911,014 new breast cancer cases were diagnosed in Asia in 2018, and the number is expected to increase by 229,650 by 2030.
Hologic, Inc. (US), GE Healthcare (US), Siemens Healthineers (Germany), Koninklijke Philips N.V. (Netherlands), Fujifilm Holdings Corporation (Japan), Canon Inc. (Japan), Aurora Healthcare US Corp. (US), Allengers (India), Dilon Technologies, Inc. (US), Planmed Oy (Finland), Delphinus Medical Technologies, Inc. (US), Micrima Limited (UK), CMR Naviscan Corporation (US), SuperSonic Imagine (France), and Carestream Health (US), among others.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
